KOLEGIJ
FARMACEUTSKA POLITIKA I ZDRAVSTVENO TRŽIŠTE
I semestar
Voditelj kolegija:
Prof.dr.sc. Igor Franceti?
Sati
14 (PREDAVANJA 8 – SEMINARI 6 ) (BROJ BODOVA 2,1)
Sadržaj
Svrha je farmacijske službe da pribavi, distribuira, kontrolira i nadzire nabavku i uporabu lijekova kako bi pacijentu terapija lijekovima bila primjerena, sigurna i troškovno u?inkovita te kako bi ostvarila o?ekivanja pacijenta, lije?nika i farmaceuta. Farmacija je struka orijentirana na informaciju, produkt i rezultat, koju društvo zadužuje za sigurnu i primjerenu uporabu lijekova.
Ispit
Pismeni
Literatura
1. Mandi? D, Oreškovi? S, Franceti? I. Oral antibiotic prescription in ambulatory care in 1999 - A contribution to the development of methods for drug consumption and prescription surveillance monitoring Collegium Antropol 25 (2): 459-465 Dec 2001
2. Franceti? I, Lasagna L, Weintrabum M, et al. Prescripton prices under the New-York Generic Substituion Law. Ann Intern. Med 92(3): 419-423
3. Quality Assurance of Pharmaceuticals: A compendium of Guidelines and Related Materials. Volume 1; WHO, Geneva 1997.
4. An International Comparision of Pharmaceutical Prices. Osterreichisches Bundesinstitut fur Gesundheitswesen, Austrian Health Institute. Vienna, 1993.
5. Essential Drugs and Other Medicines. Theme paper for Discussion: Effective Drug Regulation, What Can Countries Do?; WHO, Geneva 16-19 March 1999
6. Joseph A. Cornell. Computers in Hospital Pharmacy management, Fundamentals and Applications; An Aspen Publication, London 1983.
7. Panos Kanavos. Financing Pharmaceuticals In Transition Economies; Croatian Medical Journal 1999; 40: 244-259
8. Ingrid Rosian, Claudia Habl, Sabine Vogler. Pharmaceuticals: Market Control in Nine European Countries; Osterreichisches Bundesinstitut fur Gesundheitswesen Austrian Health Institute. Vienna; November, 1998.
9. Ramesh Govindaraj. Croatian Pharmaceutical Sector – Issues and Options. Annexx: Pharmaceutical Issues and Options. The World Bank.
10. Mrazek MF. Pharmaceutical Pricing in Developing Countries: Issues of Access to Medicines. Expert Review of Pharmacoeconomics and Outcomes Research 2(1):89-96.